Sanofi Wins EU Backing for Drugs Against Diabetes, Cancer
This article is for subscribers only.
Sanofi won European Union backing for new drugs against diabetes and colorectal cancer, helping the Paris-based drugmaker compete with products from Novo Nordisk A/S and Roche Holding AG.
The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended approval for Lyxumia as a treatment for diabetes, and Zaltrap for use with chemotherapy in adults with colorectal cancer that’s spread after initial treatment, it said in a statement today. The European Commission usually follows the committee’s recommendations.